Antibody-induced loss of Friend virus leukemia cell surface antigens occurs during progression of erythroleukemia in F1 mice by unknown
ANTIBODY-INDUCED  LOSS  OF  FRIEND  VIRUS  LEUKEMIA 
CELL  SURFACE  ANTIGENS  OCCURS  DURING 
PROGRESSION  OF  ERYTHROLEUKEMIA  IN  F1  MICE 
BY DON DOIG* AND BRUCE CHESEBRO 
From the U. S. Department of Health, Education, and Welfare, Public Health Service, National Institutes 
of Health, National  Institute  of Allergy and Infectious Diseases, Rocky Mountain  Laboratory, Hamilton, 
Montana 59840 
In  both young and  adult  mice Friend  leukemia virus  (FV) 1 causes an extremely 
rapid erythroleukemia in which the spleen is the primary site of growth of neoplastic 
cells (1-4). Splenomegaly is apparent 8-9 days after virus inoculation, at which time 
the majority of cells are infected with the virus and have virus-induced cell surface 
antigens (5, 6). Mouse strains such as DBA/2, BALB/c, and (BALB/c  ×  A/J)F1 have 
FV  viremia and  exhibit  FV-induced  cell  surface antigens  on  leukemic spleen  cells 
throughout  the course of the disease (5,  6).  However, certain Fa hybrids e.g.,  (B10.A 
×  A/WySn)Fx,  (B10.A  ×  A.BY)F1,  (C57BL/6  ×  DBA/2)F1,  and  (C57BL/10  × 
BALB/c)Fx recover from FV viremia 30-60  days after virus inoculation  in  spite of 
persistent leukemia (5). At this time these F1 hybrids have virus neutralizing antibodies 
and cytotoxic antibodies specific for FV leukemia cells (5). In the present work, it was 
found  that  30-60  days after virus inoculation  persistent  leukemic spleen  cells from 
these Fx mice were resistant to cytolysis by anti-leukemia cell antibody and comple- 
ment, and FV-induced cell-surface antigens were reduced by about 80%. This loss of 
FV-induced  cell surface antigens could also by induced  by transfer of high-antigen 
early FV spleen cells into irradiated immune recipients, and was reversed when low- 
antigen cells were transferred to irradiated nonimmune recipients. The data suggested 
that  the  loss of FV-induced  cell surface antigens  was  due  to antigenic  modulation 
caused by circulating anti-FV antibodies. This antigen loss might be responsible for 
the persistence of the leukemic spleen cells in the F1 mice studied. 
Materials and Methods 
Animals.  B10.A, A.BY,  A/WySn,  and  BIO.D2  mice were  purchased  from The Jackson 
Laboratory, Bar Harbor, Maine. B10. HTG mice were a gift from Dr. Frank Lilly, Department 
of Gene.tics, Albert  Einstein  School  of Medicine,  Bronx,  N.  Y.  F1 hybrids were bred at the 
Rocky Mountain Laboratory. 
Virus.  The B- and N-tropic strains of Friend virus (FV-B and FV-N) were obtained from 
Dr. Frank Lilly. The virus stocks were made in (B10.A  ×  A.BY)F1, (B10.A  ×  A/WySn)F1 or 
DBA/2 mice as previously described (7). 
* Predoctoral fellow in Microbiology,  Montana State University,  Bozeman,  Mont.; supported by a grant 
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leukemia. 
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Anti-FVSera.  (B10.A  ×  A.BY)FI or (B10.A  ×  A/WySn)F1 mice which had recovered from 
FV-induced splenomegaly 30-60  days  after  FV-B  inoculation (15-150  focus-forming units 
[FFU]) or 14-21 days after FV-N inoculation (1,500 FFU) were injected two to five times with 
20-25  ×  108 leukemic spleen cells obtained from syngeneic mice 8-9 days after intravenous 
inoculation with  1,500 FFU of FV-B. Mice were bled from the tail 7-14 days after the last 
injection to obtain anti-FV sera or were used as immune recipients in cell transfer experiments. 
Anti-H-2  Sera.  (C57BL/10  ×  BALB.B)F1  anti-(B10.D2  ×  BALB/c)F1  (anti-H-2  ~)  and 
(B 10.D2 ×  BALB/e)FI anti-B  10.A(2R) (anti-H-2K  k) sera were prepared as previously described 
(8). In addition, NIH contract serum D-13 (C57BL/10  ×  LP.R III) anti-B10.A(SR) (anti-H- 
2D  d) was used. 
Cell Culture.  AA41  (H-2  a)  and Y57  (H-2  b) FV-induced leukemia cell lines were grown in 
tissue culture as described  (9). Primary cultures of leukemic spleen cells were incubated in 
RPMI-1640 medium with 10% fetal calf serum and 10  -5 M 2-mercaptoethanol at 0.1-7 ×  l0  s 
viable cells per ml. 
Antibody Plus Complement (C')-Mediated  Cytotoxicity.  A two stage cytotoxicity assay in micro- 
titer trays was carried out using mouse leukemia-cell absorbed rabbit C' and SlCr-labeled target 
cells as previously described (5). Target cells were normal or leukemic spleen cells, or AA41 or 
Y57 cell lines. 
Quantitative Absorption.  Anti-H-2 or anti-FV serum was diluted to the end of the plateau of 
the titration curve in the direct cytotoxicity assay.  The serum was then absorbed with serial 
twofold dilutions of nucleated leukemic or normal spleen cells. 1-80 ×  106 cells were placed in 
separate centrifuge tubes and spun for  10 rain at 2,000 rpm. The supernate was removed, and 
the cell pellet was subjected to a  second (short)  spin and residual supernate again removed. 
Then 85 #1 of diluted serum was added to each tube, and thecell pellet was suspended. The 
serum plus cells were incubated for  1 h at 4°C, and shaken once during this time. The cells 
were spun for 10 min at 2,000 rpm in the cold and 25-#1 triplicate samples of supernate from 
each tube were dispensed to microtiter trays for assay of cytotoxicity. 
Membrane Immunofluorescence.  Spleen cells were harvested and erythrocytes were lysed with 
Tris-buffered NH4CI  for  10 rain at room temperature (10). The cells were washed twice with 
phosphate-buffered balanced salt solution plus 2% fetal calf serum and 0.01 M NaNa. 4  ×  106 
cells  were  dispensed into  10  ×  75-mm tubes and spun at  1,000 rpm  for  5  min. Indirect 
membrane immunofluorescence was  assayed as  previously described  (8), using anti-FV sera 
and  fluorescein-conjugated rabbit  anti-mouse immunoglobulin. For  the  direct  membrane 
immunofluorescence assay,  fluorescein-conjugated goat  anti-Moloney leukemia virus  (anti- 
MLV)  (obtained from the NCI Viral Ontology Program; Huntington Research Center, lot 
5010101) was absorbed twice for 40 min at room temperature with 100 mg acetone precipitated 
mouse liver and spleen tissue powder per milliliter serum and spun at 30,000 rpm for 10 rain. 
5 #1 of absorbed serum was added to the cells to be tested and the cells were resuspended and 
incubated for 20 rain at 4°C, then washed twice and examined with a fluorescence microscope. 
Cells which had visible halos or patches of membrane fluorescence were scored as positive. 
Intracellular Immunofluorescence.  50-100 #1 of washed nucleated spleen cell suspension (2-10 
x  10  s cells/ml) was placed on marked areas of microscope slides coated with 5% bovine serum 
albumin. The slides were placed in a humidity chamber, and the cells were allowed to settle 
onto the slide for 30 rain. Then the slides were placed in acetone at 4°C for 30 min or at -20°C 
for a  minimum of 12 h. After removal from the acetone, slides were immediately washed in 
phosphate-buffered saline  (PBS)  at  room  temperature  (10  rain  three  times  with  constant 
shaking), drained, and a  1/40 dilution of absorbed fluorescein-conjugated goat anti-MLV (see 
above) was  added.  The slides  were then incubated for  1 h  at  37°C in a  humidity chamber 
washed three times in PBS at room temperature, dried, mounted in buffered glycerol mounting 
medium, and examined with a fluorescence microscope. 
Irradiation.  Mice were  given 900 rads whole-body X-irradiation with a  Maximar type III 
250 KV deep therapy X-ray unit. The machine delivered 19.1 fads/rain at 24 inches from the 
target. 
Results 
Lysis of FV-Induced Leukemia  Cells with Anti-FV Cytotoxic Antibody.  Previous experi- 
ments indicated that  FV-induced leukemic spleen cells persisted  in  (B10.A  ×  A/ DON  DOIG  AND  BRUCE  CHESEBRO  1111 
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Fzo.  1.  Anti-FV antibody plus complement-mediated lysis of Fx spleen cells. Early (8-9 days 
postinfeetion) (B10.D2 × A.BY)Fz, (B10.A × A.BY)Fz,  and (B10.A × A/WySn)Fl leukemic  spleen 
cells;  late (30-90 days postinfection) (BI0.D2 ×  A.BY)Fx, (B6 ×  A/TL-)F1, (B6/TL  + ×  A)Fx, 
(B10.HTG ×  A.BY)Fz, (B10.A X A/WySn)F1 leukemic spleen cells; normal (B10 ×  A.BY)Fx or 
(B10.A × A/WySn)Fx spleen cells. All these Fz hybrids, which differed only for genes in or near the 
H-2 complex, were found to give similar results, and therefore we have combined all our data on 
different strains. 
WySn)Fz and (B10.A  ×  A.BY)F1 mice in spite of the presence of anti-FV leukemia 
cell cytotoxic antibodies  (5).  Therefore, we wanted  to determine whether  leukemia 
cells from these mice could be lysed in vitro by anti-FV serum plus rabbit C'. High 
specific lysis (20-45%)  was seen with leukemic spleen cells from 27 of 28 mice (96%) 
8-9 days after FV-B inoculation  (1,500  FFU)  (Fig.  1).  In contrast,  leukemic spleen 
cells of only 5 of 31  mice 30-90  days after FV-B inoculation  had greater than  20% 
specific lysis. These results suggested that in later stages of the disease (>30 days after 
FV inoculation)  the leukemic spleen cells of these Fa mice had reduced  amounts of 
FV-induced cell surface antigens. 
Quantitation of FV-Induced Cell Surface Antigens.  To  quantitate  and  confirm  this 
finding,  the relative amount of FV-induced  cell surface antigen  on early  (8-9  day) 
and late (30-90 day) (B 10.A  ×  A/WySn)F1 leukemic spleen cells was determined by 
quantitative absorption of cytotoxic anti-FV antisera. As seen in Fig. 2 early leukemic 
spleen cells had substantially  more FV-induced  cell surface antigen  than  late cells. 
Late leukemic spleen cells were also clearly distinguishable from normal spleen cells, 
and  late cells were capable of clearing  the  serum  of anti-FV  antibodies.  When  10 
early and  10 late leukemic Fz mice were tested in the absorption assay, it was found 
that an average of 4.0  +  1.8  ×  106 early leukemic spleen cells were required to absorb 1112 
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FIc.  2.  Absorption ofcytotoxic anti-YV serum by early and late (BI0.A  ×  A/WySn)Fx leukemic 
spleen cells. AA41 cells were used as targets in the eytotoxicity assay. 85/LI ofa Yx00 dilution of anti- 
FV serum was absorbed and the cytotoxicity assay was done in triplicate.  Mean percent specific 
cytotoxicity  values are  shown  +  standard  error.  [-1, late  cells;  O,  early  cells;  .A,  normal  cells. 
Unabsorbed anti-FV serum gave 41% specific cytotoxicity. 
85 ~1 of a 1/100 dilution of serum to 50% of maximum cytotoxicity, whereas 18.6:1:2.2 
×  106 late spleen cells were required to achieve a  similar  absorption.  Thus,  early 
spleen cells had 4.5 times more FV-induced cell surface antigen than late cells. The 
late spleen cells appeared to have lost 78% of their original FV-induced cell surface 
antigens. 
Quantitative Absorption of H-2 Surface Antigens.  We wanted  to  know whether FV- 
induced antigens were the only cell surface antigens  decreased in late stages of FV 
leukemia.  Therefore, we  compared  the  amount  of H-2  a  antigen  on  normal  and 
leukemic  spleen  cells  by  quantitative  absorption.  We  absorbed  (C57BL/10  × 
BALB.B)FI  anti-(B10.D2  ×  BALB/c)Fa  (anti-H-2  a)  serum  with  (B10.A  ×  A/ 
WySn)Fa FV leukemic spleen cells or normal spleen cells.  No difference in absorption 
of anti-H-2  a was seen when 8-9 day (early) leukemic spleen cells were compared with 
30-90 day (late) leukemic spleen cells or with normal spleen cells (Fig. 3). The K and 
D  region antigens of' the H-2 complex were also examined separately in early, late 
and normal  (B10.A  ×  A/WySn)F] mice by quantitative absorption.  No changes in 
either H-2K or H-2D antigens were observed (data not shown). 
Fluorescent Antibody Studies.  To confirm and  extend the  cytotoxic antibody data 
with an antibody binding assay, virus-induced cell surface antigens on 8-9 day and 
>30 day leukemic spleen cells from F1 mice were also studied by membrane immu- 
nofluorescence. Cells were examined using both an  indirect  (mouse anti-FV serum DON DOIG AND BRUCE CHESEBRO  1 1 13 
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Fzo. 3.  Quantitative absorption of anti-H-2  d antiserum by early and late leukemic spleen cells 
and normal spleen cells from (BI0.A ×  A/WySn)FI mice. AA41 cells were used as targets in the 
cytotoxicity assay. 85 #1 of a 1/100 dilution of anti-H-2  a serum was absorbed and the cytotoxicity 
assay was done in triplicate. Mean percent specific  cytotoxicity  values are shown :l: standard error. 
~, late (30-90 days after FV) leukemic spleen cells; C), early (8 days after FV) leukemic  spleen cells; 
A, normal spleen cells. 
followed by fluorescein-conjugated rabbit anti-mouse immunoglobulin)  (Fig. 4)  and 
a  direct  (fluorescein-conjugated goat anti-Moloney leukemia virus)  membrane fluo- 
rescence technique  (Fig. 5). Good agreement was found between the mouse and goat 
antisera  in  the  membrane fluorescence assay.  Early  (8-9  day)  FV  leukemic spleen 
cells  had  a  high  incidence  of fluorescent  cells  (65%  median)  in  the  direct  assay, 
however,  late  (>30  day)  FV  leukemia  spleen  cell  populations  had  lower  levels of 
fluorescent cells (median 19%)  (Fig. 5). Little overlap was seen between the early and 
late  percent  positive  fluorescent  ranges.  The  results  of both  indirect  and  direct 
membrane immunofluorescence tests were consistent with the cytotoxie antibody and 
quantitative absorption data found using mouse anti-FV serum, and indicated a loss 
of  FV-induced  cell  surface  antigens  in  later  stages  of leukemia.  Blocking  of FV 
antigens by circulating anti-FV antibodies in the late plasma (11)  was ruled out as a 
possible explanation for these results because the cells did not react with anti-mouse 
immunoglobulin in the indirect membrane fluorescence assay unless mouse anti-FV 
antibody was added frst  (data not shown). When acetone-fixed cells were tested for 
the presence of virus-induced cytoplasmic antigens using fluorescein conjugated goat 
anti-Moloney LV (Fig. 6), early and late F1 leukemic spleen cells were indistinguish- 
able. Early leukemic spleen cells were 50-80% positive while late leukemic spleen cells 
were 40-80% positive. Thus, it appeared that the loss of virus-induced cell membrane 
antigens from late FV leukemic spleen cells was a cell surface phenomenon since viral 
antigens were present in the cytoplasm of the late leukemic spleen cells. 
In  Vivo Reconstitution Experiments.  The decrease in FV-indueed cell surface antigens 
on late (B10.A  ×  A/WySn)F1 leukemic spleen cells was found to be reversible after 
adoptive  transfer  of these  cells  into  lethally  irradiated  unimmunized  mice.  Late 
(B10.A  ×  A/WySn)Fa hybrid leukemic spleen cells (H-2  a/a were injected into lethally 1114  FRIEND  VIRUS  LEUKEMIA  CELL  SURFACE  ANTIGENS 
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Fro.  4.  Percentage ofcel|s showing virus-specific membrane fluorescence in the indirect membrane 
fluorescence assay. Leukemic or normal nucleated spleen cells were  reacted with  either anti-~ 
serum or normal mouse serum, then washed and reacted with fluo~ein-conjugated rabbit anti- 
mouse immunoglobulin. Percent virus-specific membrane fluorescence was calculated by subtracting 
the  value obtained  when the cells were  reacted  first  with  normal mouse serum from the value 
obtained with anti-FV serum. Each point represents one mouse spleen. 100-200 cells were counted 
per sample. Early leukemic spleen cells were 8-9 days post-FV infection from (B10.A  ×  A)F1 mice. 
Late leukemic spleen cells were 30-90 days post-FV infection from (B10.A  ×  A)F1,  (B6/TL  +  × 
A)F1 and (B6  ×  A/TL-)F1 mice. Normal (B10.A  ×  A)FI spleen cells were used as controls. 
irradiated (900 rads)  (B 10.A  ×  A.BY)FI congenic hybrids (H-2a/b). The spleens were 
harvested 6-7 days after injection, and the cells were analyzed by immunofluorescence 
for FV-induced cell-surface antigens and  for FV-induced cytoplasmic antigens. As 
seen in Table I late F1 leukemic spleen cells transferred into unimmunized lethally 
irradiated recipients showed an increased percent (51-66%)  of cells positive for FV- 
specific  membrane  immunofluorescence. These  values  were  similar  to  those  seen 
previously in early (8-9 day) spleen cell populations (Fig. 5). Late F1 cells transferred 
to  immune  lethally irradiated  recipients  failed  to  show  this  increase.  Recovered 
leukemic cells from both immune and nonimmune recipients were found to have high 
levels of cytoplasmic virus-specific fluorescence  (63-92%)  when  acetone-fixed cells 
were examined. This indicated that virus-infected leukemia cells were not eliminated 
after transfer to either type of recipient. 90 
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FIG.  5.  Percent  virus-specific membrane  fluorescence in  the  direct  assay.  Leukemic or  normal 
(B10.A  ×  A)F1  spleen cells were reacted directly with fluorescein-conjugated goat anti-Moloney 
LV serum. Early leukemic cells were 8-9 days post-FV infection. Late leukemic cells were 30-90 
days post-FV infection. Each point represents one mouse spleen. 
Early  (8-9  day)  leukemic spleen  cells  (66-76%  positive membrane  fluorescence) 
were similarly transferred to nonimmune and immune lethally irradiated recipients. 
6-7 days after transfer into immune lethally irradiated recipients, 9-28% of recovered 
spleen cells were positive for membrane fluorescence (Table II). The percent of cells 
positive for FV-induced cell membrane antigens remained high when the early spleen 
cells were transferred to unimmunized lethally irradiated recipients. In both types of 
recipient, cytoplasmic virus-specific fluorescence was seen  in  53-62%  of the spleen 
cells recovered 6-7 days after transfer. 
In  Vitro Studies.  Experiments were carried out to attempt to increase the expression 
of FV antigen on late Fx leukemic spleen cells by incubating the cells in vitro in the 
absence of antibody. Washed late FV leukemic spleen cells were placed in culture at 
37°C  for various times from  1 to  72  h. The late FV spleen cells failed to show an 
increase in  virus-induced cell surface antigens beyond initial levels, as assayed by 
direct membrane immunofluorescence (data not shown). In converse experiments, 8-9 
day (early) FV leukemic spleen cells were placed in tissue culture for 1-48 h at 37°C 
with  high concentrations of cytotoxic anti-FV  antisera  (1:4  or  1:5).  However,  no 
decrease in cell surface FV-induced antigen concentration was observed  (data not 1116  FRIEND  VIRUS  LEUKEMIA  CELL  SURFACE  ANTIGENS 
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FxG. 6.  Percentage  of virus-specific intracellular  fluorescence in  acetone-fixed spleen cells from 
(BI0.A  X  A/WySn)F1  mice  reacted  with  fluoresceln-conjugated goat  anti-Moloney  LV.  Early 
leukemic cells were  8-9  days  post-FV  infection.  Late  leukemic cells  were  30-90  days  pnst-FV 
infection. Each pont represents one mouse spleen. 
shown). By indirect immunofluorescence and by cytotoxicity, the antibodies appeared 
to bind to the cell surface and remained there for the duration of the incubation  (up 
to 48 h).  No evidence for antigenic  modulation  was seen. Thus, we were unable to 
induce increased expression of FV-induced antigens on the leukemic spleen cells nor 
were we able to cause an antibody-mediated decrease or modulation of FV-induced 
cell membrane antigens in vitro. 
Discussion 
Leukemic spleen cells from (B10.A  ×  A.BY)F1  and  (B10.A  ×  A/WySn)F1  mice 
had  reduced  amounts  of  FV-induced  cell  surface  antigen  30-90  days  after  FV 
inoculation  as compared to cells taken 8-9 days after inoculation.  This was shown 
with fluorescent antibody, quantitative absorption and antibody plus C' cytotoxicity. 
In vivo blocking of FV antigens by anti-FV antibody was ruled out as an explanation 
for these results by the indirect  membrane fluorescence assay, which  indicated  that 
cells did not react with anti-immunoglobulin unless anti-FV antibody was added first. 
When  FV-induced  cell surface antigens were lost intracellular  FV-induced antigens DON  DOIG  AND  BRUCE  CHESEBRO 
TABLE  I 
In  Vivo Reappearance of FV-Induced Cell Surface Antigens on Late F1 
Leukemic Spleen Cells 
1117 
Experiment 
Membrane fluorescence* 
900 rad Nonim-  900 rad Immune  Donor  mune recipients  recipients:~ 
% 
1  36  57  15 
2  37  61  30 
3  6  51, 54, 51  17, 18 
4  19  59, 54  18, 25 
5  38  66  NT§ 
6  8  51  NT 
* Late (30-90 days) (BI0.A  ×  A/WySn)F1 leukemic spleen cells (1-3  ×  107) 
were  transferred  into  lethally  irradiated  (900  rads)  congenic  (B10.A  × 
A.BY)Fx hybrids which were either normal or previously immunized against 
FV-induced cell surface antigens. Recipient spleen cells were examined for 
viral antigens by immunofluorescence 6-7 days after cell transfer. Percent of 
cells showing direct  membrane immune  fluorescence with fluoreseeinated 
goat anti-Moloney LV serum.  100-200  cells were counted per population. 
All spleen cells recovered from donor mice or from recipient mice 6-7 days 
after transfer had high percentages of cells (63-92%) which were positive for 
cytoplasmic viral antigens by immunofluorescence analysis of acetone-fixed 
cells. In both types of recipients the spleen cells were of donor H-2 type as 
determined by direct eytotoxicity typing. 
:~ (B10.A  ×  A.BY)Fx  mice  which  had  recovered  from  FV  leukemia  were 
repeatedly boosted with 8-day syngeneic leukemic spleen cells, and had high 
titers of circulating anti-FV cytotoxic antibodies at the time of irradiation. 
§ NT, not tested. 
TABLE  II 
FV-Induced Cell Surface Antigen Loss on Early (8-9 Day) Leukemic Spleen 
Cells Transferred to Lethally Irradiated Immune Recipients 
Experiment 
Membrane fluorescence* 
900 rad Nonim-  900 rad Immune  Donor  mune recipients  recipients:]: 
% 
1  70  60, 63  9, 20 
2  66  66  10,  17 
3  76  75, 70  26,  18 
4  68  66, 64  13, 28 
* 8-9 day  (early)  (B10.A  X  A/WySn)F1  leukemic spleen cells (1-3  X  107) 
were  transferred  into  lethally  irradiated  (900  rads)  congenic  (B10.A  X 
A.BY)F1  hybrids which were either normal or previously immunized against 
FV-induced cell surface antigens. Recipient spleen cells were examined for 
viral antigens by immunofluorescence 6-7 days after cell transfer. Percent of 
cells showing direct  membrane  immune  fluorescence with  fluoresceinated 
goat anti-Moloney LV serum. All spleen cells recovered from donor mice or 
from recipient  mice 6-7  days after transfer had  high percentages of cells 
(53-62%) which were positive for cytoplasmic viral antigens by immunoflu- 
orescence analysis of acetone-fixed cells. 
~: (BI0.A  ×  A.BY)F1  mice  which  had  recovered  from  FV  leukemia  were 
repeatedly boosted with 8-day syngeneic leukemic spleen cells, and had high 
titers of circulating anti-FV cytotoxic antibodies at the time of irradiation. 1118  FRIEND VIRUS LEUKEMIA CELL SURFACE ANTIGENS 
were still present. The membrane antigen loss observed appeared to be specific for FV 
antigens since there was no concomitant change in the expression of H-2 antigens at 
8-9 and >30 days, as determined by quantitative absorption. The loss of FV-induced 
cell surface antigens on late leukemic spleen cells was seen only with F1 hybrids which 
had B 10.A or other B 10 congenic mice as one parent. The A.BY and A/WySn parents 
did not lose FV-induced cell surface antigens in late stages of the disease.  2 
Evidence for the reversibility of the loss of FV-induced cell membrane antigens was 
obtained by transferring late leukemic spleen cells to lethally irradiated recipients. 
FV-induced cell surface antigens  reappeared within  6-7  days after transfer of late 
leukemic spleen cells to nonimmune irradiated  hosts,  but  failed to reappear if the 
irradiated  host  had  been  previously immunized  against  FV  leukemic spleen  cells. 
Conversely, 8-9 day leukemic spleen cells expressing high levels of FV-induced cell 
surface antigens lost antigen 6-7 days after transfer to previously immune irradiated 
recipients, but failed to lose antigen when transferred to normal irradiated recipients. 
These  results  suggested  an  involvement of the  anti-viral  immune  response  in  the 
induction or maintenance of FV-induced cell-surface antigen loss  in the irradiated 
immune recipients. Preliminary data suggest that similar immune mechansims may 
also  be  responsible  for the  loss  of FV-induced  antigens  seen  in  late  stages  of FV 
leukemia  in  (B10.A  ×  A/WySn)F1  mice. The  F1  hybrid mice have  demonstrable 
circulating cytotoxic anti-leukemia cell antibody 30 days or later after FV infection, 
and  the  time  course  of FV  antigen  loss  corresponds  with  the  rise  in  circulating 
cytotoxic antibody titer.  2 Furthermore, A.BY and A/WySn parents of these F1 hybrids 
which do not develop circulating cytotoxic anti-leukemia cell antibodies, do not show 
a decrease in FV-induced cell surface antigen during the course of the disease. 
The mechanism of the reappearance of FV antigen on the late leukemic spleen cells 
injected into irradiated recipients is not completely clear. Antigen may be re-expressed 
on  the  original  low  antigen  donor cell population  and  their  progeny, or  residual 
antigen positive leukemic cells may grow out after transfer to irradiated recipients. 
However, preliminary data indicate that pretreatment of the late leukemic spleen cell 
population with anti-FV antisera plus C' to kill residual antigen positive cells prior to 
injection into irradiated nonimmune recipients does not alter antigen re-expression 
(data not shown). This finding appears to exclude the possibility of the outgrowth of 
residual high antigen cells after adoptive transfer. Furthermore, since the same percent 
of cells was positive for virus-specific cytoplasmic fluorescence in the donor and the 
recipient spleens, it seems most likely that antigen was re-expressed on virus-infected 
cells after transfer to unimmunized recipients. 
Since we had demonstrated the reversibility of the FV membrane antigen loss  in 
vivo in a nonimmune environment, we attempted to induce a similar antigen increase 
in vitro. We were unable to observe an increase in FV-induced cell surface antigens 
on late F1 leukemic spleen cells when these cells were placed in tissue culture in the 
absence of anti-FV antibody. Conversely, since it was likely that cytotoxic antibody 
was  involved  in  the  induction  of FV  surface  antigen  loss  observed  in  vivo,  we 
attempted to induce a decrease in FV-induced cell surface antigen on early leukemic 
spleen cells by placing these cells in cultures with high concentrations of cytotoxic 
anti-FV serum. We were unable to decrease FV surface antigen on early cells with 
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this technique, and were even unable to decrease antigen by using an anti-FV/anti- 
immunoglobulin sandwich technique (data not shown). Old et al.  (12)  were able to 
cause  a  selective loss  of TL  (thymus-leukemia)  antigens  on  ascites  leukemia  cells 
cultured  in  vitro  in  the  presence of anti-TL antisera,  and  in  vivo in  immunized 
recipients (13).  TL antigenic modulation was quite rapid and was shown to be an 
active  metabolic  process.  The  reappearance  of TL  antigen  when  the  cells  were 
cultured in the absence of anti-TL antibody was less rapid, and may have required 
several cell divisions  (12). Genovesi et al.  (14)  observed modulation of FV antigen 
from the cell surface of a  FV tumor line when incubated in vitro in the presence of 
anti-FV antibody. Antigenic modulation was seen to a greater extent when the cells 
were in  logarithmic  growth  as compared to cells in  a  resting state.  Failure of FV 
leukemic spleen cells to divide in vitro may explain why we were unable to induce in 
vitro modulation  of FV  antigens  on  early leukemic spleen  cells  or to observe FV 
antigen  reappearance on late cells cultured  in  vitro.  On  the other hand,  it  is  also 
possible  that  the  FV  antigen  loss  observed  in  vivo with  leukemic  spleen  cells  is 
substantially different from the antigenic modulation described with the TL system 
and with a FV tumor cell line in vitro. 
Late  F1  leukemic  spleen  cells  retained  intracellular  or  cytoplasmic  FV-induced 
antigens while their surface antigens were lost. Ioachim et al.  (15), found a  similar 
disjunction  between  membrane  and  cytoplasmic  Gross  murine  leukemia  virus 
(MuLV)  antigen  expression  when  G-MuLV  lymphoma  cells  were  injected  into 
partially  tolerized  rats.  Thus  in  both  FV  and  G-MuLV  systems,  leukemia  cells 
sometimes exhibit surface antigenic adaptations to immune pressures without altering 
intracellular antigen expression. This may be a  means by which tumor cells escape 
immune destruction (16). It is clear that the presence of cytotoxic anti-leukemia cell 
antibodies is not by itself sufficient to cause a recovery from leukemia (5). This may 
be because the leukemic cells become insensitive to antibody-mediated lysis as a result 
of a loss of FV-induced cell surface antigens. Similar findings have been reported for 
measles-virus infected cells which can also grow normally in the presence of cytotoxic 
anti-measles antibody (11). In vivo studies of suppression of tumor-specific cell surface 
antigen expression (17,  18) have involved transfer of tumor cells to immune recipients 
in order to induce antigen loss. Ioachim et al. (15, 19) reported that transfer of Gross 
MuLV  lymphoma cells  to  immune  recipients induced  a  decreased  tumor  antigen 
expression,  and  this  antigen  loss  was  associated  with  increased  tumorigenicity on 
subsequent  transfer.  In  the present  study, adoptive transfer of tumor cells was  not 
required to induce antigen loss, and the observed decreased antigen expression may 
represent  a  tumor cell adaptation  to host  immune  pressures  generated  during the 
course of FV leukemia. 
Summary 
Friend virus  (FV)-induced leukemic spleen cells from  (B10.A  X  A)F1 mice were 
found to lose sensitivity to antibody-mediated lysis during progression of erythroleu- 
kemia.  This was  correlated with a  78%  loss  of FV-induced cell surface antigens  as 
determined by quantitative absorption of cytotoxic antibodies and with a  decreased 
percentage of leukemic  spleen  cells  showing  membrane  immunofluorescence with 
anti-FV antibody. Antigen loss was observed only with virus-induced antigens, and 
was  limited  to  antigens  expressed  on  the  cell  surface.  FV-induced  antigens  were 1120  FRIEND VIRUS LEUKEMIA CELL SURFACE  ANTIGENS 
regained  when  low-antigen  leukemia  cells  from  late  stages  of the  leukemia  were 
transferred to lethally irradiated nonimmune recipients, but not when these cells were 
transferred  to  hyperimmune  lethally  irradiated  recipients.  Conversely,  when  high- 
antigen leukemic spleen cells from early stages of the erythroleukemia were transferred 
to hyperimmune irradiated recipients, antigen loss was induced. The immune response 
to virus-induced  antigens  appeared  to be involved in causing the antigenic  changes 
observed on leukemia cells in this system. 
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